AEMD · Aethlon Medical Inc · Metrics
$4.84
-0.27 (-5.28%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.78M
Shares
1.61M
Volume · Nov 19
20.26K
Avg daily vol (3M)
2.52M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
AEMD metrics
54 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$4.84
Market cap
$7.78M
Price action
23 metricsPrice change (1W)
-7.6%
Price change (30D)
-1.0%
Price change (3M)
+83.8%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$24.20
52-week low
$1.43
Change from 52-week high
-78.9%
Change from 52-week low
+257.3%
Annualized volatility
692.8%
Annualized volatility (3M)
743.6%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
45.1
Price vs SMA 50
-4.0%
Price vs SMA 200
—
Avg volume (3M)
2.52M
Relative volume
0.0
Average dollar volume
$12.66M
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
1.61M
Valuation
12 metricsP / E (TTM)
3.5
Trailing earnings · reciprocal yield 28.4%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.4
reciprocal yield 73.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-98.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-13
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$8.25M
Net income (TTM)
−$8.07M
Trailing 12 months
Diluted EPS (TTM)
$1.45
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,167.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-133.3%
Return on assets
-110.0%
Debt / equity
—
Current ratio
5.4
EBITDA (TTM)
−$7.93M
Free cash flow (TTM)
—
Quick ratio
5.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$6.49M
Latest balance sheet
Cash & equivalents
$6.49M
Total assets
$7.33M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$7.26M
Capital expenditures (TTM)
$15,019
R&D (TTM)
$2.12M
SG&A (TTM)
—
Stock compensation (TTM)
$233,663
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
17
13F filer change QoQ
0
Institutional ownership
32.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
59.7%
Private-fund adviser ownership
42.5%
Active holders' share change QoQ
+917.2%
Holder tenure
1.4
Price vs estimated holder cost
-37.0%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.2%
Short interest
3 metricsShort interest
2.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
60 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
882291
CUSIP
00808Y703
13F (30d)
16 filings
16 filers
Visit website
Investor relations